Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021
El objetivo es caracterizar el espectro de la enfermedad por hígado graso no alcohólico de causa metabólica (EHGNA) y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes adultos con diagnóstico de Diabetes Mellitus tipo 2 atendidos de forma ambulatoria en Barranquilla-Colom...
- Autores:
-
Bornacelly Mendoza, Adriana Paola
Castillo Nevado, Oswaldo Jesús
- Tipo de recurso:
- Fecha de publicación:
- 2023
- Institución:
- Universidad Libre
- Repositorio:
- RIU - Repositorio Institucional UniLibre
- Idioma:
- OAI Identifier:
- oai:repository.unilibre.edu.co:10901/27874
- Acceso en línea:
- https://hdl.handle.net/10901/27874
- Palabra clave:
- Diabetes mellitus
Enfermedad por hígado graso no alcohólico - EHGNA
Factor de riesgo cardiovascular
Síndrome coronario agudo
Fibrilación auricular
Diabetes mellitus
Non-alcoholic Fatty Liver Disease - NAFLD
Heart disease risk factors
Acute coronary syndrome
Atrial fibrillation
Hígado graso
Diabetes mellitus
Enfermedades cardiovasculares
- Rights
- License
- http://purl.org/coar/access_right/c_abf2
| id |
RULIBRE2_b262d7d19309bdfc0459dcbd99721cb2 |
|---|---|
| oai_identifier_str |
oai:repository.unilibre.edu.co:10901/27874 |
| network_acronym_str |
RULIBRE2 |
| network_name_str |
RIU - Repositorio Institucional UniLibre |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 |
| title |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 |
| spellingShingle |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 Diabetes mellitus Enfermedad por hígado graso no alcohólico - EHGNA Factor de riesgo cardiovascular Síndrome coronario agudo Fibrilación auricular Diabetes mellitus Non-alcoholic Fatty Liver Disease - NAFLD Heart disease risk factors Acute coronary syndrome Atrial fibrillation Hígado graso Diabetes mellitus Enfermedades cardiovasculares |
| title_short |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 |
| title_full |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 |
| title_fullStr |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 |
| title_full_unstemmed |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 |
| title_sort |
Caracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021 |
| dc.creator.fl_str_mv |
Bornacelly Mendoza, Adriana Paola Castillo Nevado, Oswaldo Jesús |
| dc.contributor.advisor.none.fl_str_mv |
Cano Peñaloza, Raquel Amira Moreno Pallares, Eiman Varela Prieto, Lourdes |
| dc.contributor.author.none.fl_str_mv |
Bornacelly Mendoza, Adriana Paola Castillo Nevado, Oswaldo Jesús |
| dc.subject.spa.fl_str_mv |
Diabetes mellitus Enfermedad por hígado graso no alcohólico - EHGNA Factor de riesgo cardiovascular Síndrome coronario agudo Fibrilación auricular |
| topic |
Diabetes mellitus Enfermedad por hígado graso no alcohólico - EHGNA Factor de riesgo cardiovascular Síndrome coronario agudo Fibrilación auricular Diabetes mellitus Non-alcoholic Fatty Liver Disease - NAFLD Heart disease risk factors Acute coronary syndrome Atrial fibrillation Hígado graso Diabetes mellitus Enfermedades cardiovasculares |
| dc.subject.subjectenglish.spa.fl_str_mv |
Diabetes mellitus Non-alcoholic Fatty Liver Disease - NAFLD Heart disease risk factors Acute coronary syndrome Atrial fibrillation |
| dc.subject.lemb.spa.fl_str_mv |
Hígado graso Diabetes mellitus Enfermedades cardiovasculares |
| description |
El objetivo es caracterizar el espectro de la enfermedad por hígado graso no alcohólico de causa metabólica (EHGNA) y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes adultos con diagnóstico de Diabetes Mellitus tipo 2 atendidos de forma ambulatoria en Barranquilla-Colombia de julio a diciembre de 2021. Se realizó una estudio observacional descriptivo documental con revisión de historias clínicas de corte retrospectiva con un componente analítico entre EHGNA en pacientes diabéticos y desenlaces cardiovasculares mayores no fatales. Se incluyeron 309 personas con diabetes atendidos en dos instituciones de referencia en Barranquilla: la Clínica General del Norte (CGN, n=162) y MiRed IPS (n=147), la prevalencia global de EHGNA fue del 67%, la esteatosis correspondió a un 50,81% (n=157), la esteatosis con algún grado de fibrosis ya sea significativa o avanzada se encontró en el 3,88% (n=12) y la cirrosis en el 12% (n=38), aportando una prevalencia global de fibrosis del 16,18% (n=50). La ecografía fue el estudio imagenológico más empleado para la detección y diagnóstico de esteatosis, la elastografía transitoria se realizó solo en 54 pacientes (17,48%). La prevalencia de obesidad en pacientes con diabetes y EHGNA fue del 36,82%, siendo la obesidad grado 1 la categoría más frecuente, la hipertensión arterial se presentó en el 76,33% de los casos, la dislipidemia en el 73,43%. Se encontró una mayor proporción de desenlaces cardiovasculares mayores no fatales como síndrome coronario agudo y fibrilación auricular en los pacientes con EHGNA (OR: 1,94; 95% IC:1,05-3,66; p=0.04). la conclusión es que la prevalencia de EHGNA en pacientes diabéticos atendidos en Barranquilla es del 67%, la prevalencia de fibrosis fue del 16,18%; además se observó una tendencia con efecto de riesgo con una mayor proporción de desenlaces cardiovasculares mayores no fatales como síndrome coronario agudo y fibrilación auricular en los pacientes con EHGNA (OR: 1,94; 95% IC:1,05-3,66; p=0.04) por lo que se requieren estudios analíticos adicionales que profundicen en el efecto de riesgo de EHGNA en la morbilidad cardiovascular. |
| publishDate |
2023 |
| dc.date.accessioned.none.fl_str_mv |
2023-12-13T21:01:13Z |
| dc.date.available.none.fl_str_mv |
2023-12-13T21:01:13Z |
| dc.date.created.none.fl_str_mv |
2023 |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.local.spa.fl_str_mv |
Tesis de Especialización |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10901/27874 |
| url |
https://hdl.handle.net/10901/27874 |
| dc.relation.references.spa.fl_str_mv |
Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Vol. 10, Nature Reviews Gastroenterology and Hepatology. 2013. p. 330–44 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Alimentary Pharmacology and Therapeutics 2018; 48(7):696-703 Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports 2021; 21 (5):15 Kaya E, Yilmaz Y. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. Journal of Clinical and Translational Hepatology 2022; 10 (2); 329-338 Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology 2021; 18 (4): 223-238 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019; 70 (3): 531-544 Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver 54 Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice. 2022;28(5):528–62 Rinella ME, Neuschwander-Tetri BA, Shadab Siddiqui M, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77:1797–835 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020; 69 (9): 1691-1705 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357 Chen X, Ma T, Yip R, Perumalswami P V., Branch AD, Lewis S, et al. Elevated prevalence of moderate-tosevere hepatic steatosis in World Trade Center General Responder Cohort in a program of CT lung screening. Clin Imaging. 2020;60(2):237–43 Chen X, Li K, Yip R, Perumalswami P, Branch AD, Lewis S, et al. Hepatic steatosis in participants in a program of low-dose CT screening for lung cancer. Eur J Radiol. 2017; 94:174–9 Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ, et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. American Journal of Roentgenology. 2010;194(3):623–8 Ochoa C. E, Calambás F. Hígado graso no alcohólico en consulta de gastroenterología. Repertorio de Medicina y Cirugía. 2017;26(4):225–30 Prieto Ortiz JE, Pardo SS, Díaz LR, Pacheco SH. Hígado graso: Aspectos clínicos en un centro de tercer nivel en Bogotá - Período 2009-2013. Rev Colomb Gastroenterol. 2014;29(2):117–24 Vanegas R. CM, Restrepo R. C, Vargas G. N, Marín C. AE, Martínez S. LM, Yepes D. CE, et al. Characterization of patients with non-alcoholic fatty liver disease in a highly complex colombian hospital in 2013. Rev Colomb Gastroenterol. 2014;29(4):342–6 Escorcia E;, Marrugo W. Caracterización epidemiológica y clínica de la cirrosis hepatica en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017. Biociencias. 2018;13(1):17–30 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes and Metabolism 2021; 47 (2): 101215 Bejarano Ramírez DF, Carrasquilla Gutiérrez G, Porras Ramírez A, Vera Torres A. Prevalence of liver disease in Colombia between 2009 and 2016. JGH Open 2020; 4: 603-610 Prieto O JE, Sánchez P S, Prieto RG, Rojas D EL, González L, Mendivelso F. Características clínicas y descompensación en pacientes con cirrosis hepática atendidos en dos centros de hepatología en la ciudad de Bogotá D.C., 2010-2014. Revista Colombiana De Gastroenterología 2016; 31(1): 1–8 Giraldo-Montoya Ángela M., Barraza-Amador M, Villa-Velásquez H, Martínez JW, Garcia-Castro G. Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012. Rev Méd Risaralda 2014; 20 (2):8686-94 Lambis L, Belisario Solana J, Gastelbondo B, Romero D, Garrido D, Puello W, et al. Factores de riesgo asociados a hígado graso de origen no alcohólico en una población del Caribe Colombiano. Rev Col Gastroenterol 2016; 31 (2): 89-95 Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. The Lancet 2021; 397: 2212–24. Elsevier B.V Perez M, Gonzáles L, Olarte R, Rodríguez NI, Tabares M, Salazar JP, et al. Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Prev Med (Baltim). 2011;52(2):174– 7 López-Velázquez JA, Silva-Vidal K V., Ponciano-Rodríguez G, Chávez-Tapia NC, Arrese M, Uribe M, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Annals of Hepatology 2014;13(2):166-78 Rojas YAO, Cuellar CLV, Barrón KMA, Arab JP, Miranda AL. Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysis. Annals of Hepatology 2022; 27(6):100706 Budd J, Cusi K. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? American Journal of Medicine 2020;133(5):536-543 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, et al. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus. 2021;13(8): e17321 Dokmak A, Lizaola-Mayo B, Trivedi HD. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. American Journal of Medicine 2021; 134 (1): 23-29. Elsevier Inc Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology 2018; 15(1):11-20. Nature Publishing Group Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology 2018; 14 (2): 88-98 Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, et al. NAFLD/NASH in patients with type 2 diabetes and related treatment options. Journal of Endocrinological Investigation 2018; 41(5): 509-521 Glovaci D, Fan W, Wong ND. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Current Cardiology Reports 2019; 21 (4): 21 Vargas-Uricoechea H, Casas-Figueroa LÁ. An Epidemiologic Analysis of Diabetes in Colombia. Annals of Global Health 2015;81(6):742-53 Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Erratum: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018; 392(10160):1736- 1788 Younossi ZM, Felix S, Jeffers T, Younossi E, Lam B, Nader F, et al. Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. Clinical Gastroenterology and Hepatology 2022; 20(5): e1149-e1156 Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology 2022;42(6): e168-e185 Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatology Communications 2018; 2(4):376-392 Motamed N, Rabiee B, Poustchi H, Dehestani B, Hemasi GR, Khonsari MR, et al. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol. 2017;41(1):31–8 Lee SB, Park GM, Lee JY, Lee BU, Park JH, Kim BG, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. J Hepatol. 2018;68(5):1018–24 Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600 Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254(2):393–400 Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS, et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World Journal of Gastroenterology 2013; 19(38): 6453–6457 Perera N, Indrakumar J, Abeysinghe WV, Fernando V, Samaraweera WMCK, Lawrence JS. Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: An observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16(1):37 Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2017; 11 Suppl 1: S209-S216 Keskin M, Hayıroğlu Mİ, Uzun AO, Güvenç TS, Şahin S, Kozan Ö. Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST–Segment Elevation Myocardial Infarction. American Journal of Cardiology. 2017;120(10):1720–6 Tsang SWC, Ng WF, Wu BPY, Chow DA, Li ETH, Wong TC. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia). 2006;21(1 PART1):116–21 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clinical Research in Cardiology 2021; 110(7):921-937 Vasunta RL, Kesäniemi YA, Ylitalo AS, Ukkola OH. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. J Hypertens. 2012;30(10):2015–9 Alkagiet S, Papagiannis A, Tziomalos K. Associations between nonalcoholic fatty liver disease and ischemic stroke. World Journal of Hepatology 2018; 10(7): 474–47 Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology 2018;15(7):425- 439 Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One. 2015;10(8): e0135329 Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Valbusa F, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism. 2015;64(8):879–87 Bonapace S, Valbusa F, Bertolini L, Pichiri I, Mantovani A, Rossi A, et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One. 2014 Feb 5;9(2): e88371 Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study). PLoS One. 2015;10(11): e0142937 Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. Liver International. 2019;39(4):758-769 Long MT, Yin X, Larson MG, Ellinor PT, Lubitz SA, McManus DD, et al. Relations of liver fat with prevalent and incident atrial fibrillation in the framingham heart study. J Am Heart Assoc. 2017;6(5): e005227 Lee SR, Han K Do, Choi EK, Oh S, Lip GYH. Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. Sci Rep. 2021;11(1):3737 Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402 Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl): S17–31 Saavedra-Chacón MF, Pérez S, Guevara LG, Saavedra-Chacón MF, Pérez S, Guevara LG. Enfermedad del hígado graso asociada con la disfunción metabólica. Una nueva propuesta para una dolencia en auge. Iatreia. 2021;34(3):241–52 Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Curr Pharm Des. 2019;24(38):4574–86 Graffigna M, Catoira N, Soutelo J, Azpelicueta A, Berg G, Perel C, et al. Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes. Rev Argent Endocrinol Metab. 2017;54(1):37–46 Wells MM, Li Z, Addeman B, Mckenzie CA, Mujoomdar A, Beaton M, et al. Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. Can J Gastroenterol Hepatol. 2016; 2016:4930987 Castera L, Yuen Chan HL, Arrese M, Afdhal N, Bedossa P, Friedrich-Rust M, et al. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64 Boyum JH, Atwell TD, Schmit GD, Poterucha JJ, Schleck CD, Harmsen WS, et al. Incidence and Risk Factors for Adverse Events Related to Image-Guided Liver Biopsy. Mayo Clin Proc. 2016;91(3):329–35 Stoopen-Rometti M, Encinas-Escobar ER, Ramirez-Carmona CR, Wolpert-Barraza E, Kimura-Hayama E, Sosa-Lozano LA, et al. Diagnóstico y cuantificación de fibrosis, esteatosis y hepatosiderosis por medio de resonancia magnética multiparamétrica. Revista de Gastroenterologia de Mexico 2017; 82(1):32-45 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Vol. 20, World Journal of Gastroenterology. 2014. p. 475–85 Castellana M, Donghia R, Guerra V, Procino F, Lampignano L, Castellana F, et al. Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. A meta-analysis. J Clin Med. 2021;10(9):1877 Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics. 2022;12(2):407 Rada G, Roa M. Qué son y cómo se interpretan los outcomes compuestos. Rev Med Chil. 2009;137(11):1523–6 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal 2020; 41:111-188 Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl 1):S158– S190 Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl 1): S49–S67 Schattenberg JM, Allen AM, Jarvis H, Zelber-Sagi S, Cusi K, Dillon JF, et al. A multistakeholder approach to innovations in NAFLD care. Communications Medicine. 2023;3(1 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801 Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43(1):83- 95 Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471–8 Kwok R, Choi KC, Wong GLH, Zhang Y, Chan HLY, Luk AOY, et al. Screening diabetic patients for nonAlcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut. 2016;65(8):1359–68 Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. 2021;121:154752 Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2018;16(2):198-210.e2 Han S, Choi M, Lee B, Lee HW, Kang SH, Cho Y, et al. Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gut Liver. 2022;16(6):952–63 Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of noninvasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis. Gut 2022; 71:1006–1019 Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A metaanalysis study. Hepatology Research 2016; 46(9):862-70 Pérez-Gutiérrez OZ, Hernández-Rocha C, Candia-Balboa RA, Arrese MA, Benítez C, Brizuela-Alcántara DC, et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Ann Hepatol. 2013;12(3):416–24 Aschner P, Gagliardino JJ, Ilkova H, Lavalle F, Ramachandran A, Mbanya JC, et al. Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia. 2020;63(4):711–21 Huayanay-Espinoza IE, Guerra-Castañon F, Lazo-Porras M, Castaneda-Guarderas A, Thomas NJ, GarciaGuarniz AL, et al. Metabolic control in patients with type 2 diabetes mellitus in a public hospital in Peru: A cross-sectional study in a lowmiddle income country. PeerJ. 2016;2016(10): e2577 Osuna Pérez M, Rivera MC, Bocanegra C de J, Lancheros A, Tovar H, Hernández JI, et al. Caracterización de la diabetes mellitus tipo 2 y el control metabólico en el paciente hospitalizado. Acta Médica Colombiana. 2014;39(4):344–51 Meyersohn NM, Mayrhofer T, Corey KE, Bittner DO, Staziaki P V., Szilveszter B, et al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clinical Gastroenterology and Hepatology. 2021;19(7):1480-1488.e14 Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867–75 Ismaiel A, Popa SL, Dumitrascu DL. Acute coronary syndromes and nonalcoholic fatty liver disease: “Un affaire de coeur.” Canadian Journal of Gastroenterology and Hepatology 2020; 30:8825615 van Kleef LA, Lu Z, Arfan Ikram M, de Groot NMS, Kavousi M, de Knegt RJ. Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study. J Hepatol. 2022;77(4):931–8 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.format.spa.fl_str_mv |
PDF |
| dc.coverage.spatial.spa.fl_str_mv |
Barranquilla |
| institution |
Universidad Libre |
| bitstream.url.fl_str_mv |
http://repository.unilibre.edu.co/bitstream/10901/27874/5/Bornacelly.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/27874/6/BORNACELLY.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/27874/7/FORMULARIO%20AUTORIZACION.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/27874/3/license.txt http://repository.unilibre.edu.co/bitstream/10901/27874/1/BORNACELLY.pdf http://repository.unilibre.edu.co/bitstream/10901/27874/2/FORMULARIO%20AUTORIZACION.pdf |
| bitstream.checksum.fl_str_mv |
96871d7132094f77451a2dc4998a3b8e 0e23061c2ed41f730db0ea3e882a467e 866424b5b768a79ad3f5670dcfda3d6c 8a4605be74aa9ea9d79846c1fba20a33 ca42e0bf20d3691ab4c004c24ad6ae9b 500a42f7f8c0d6a15b257b46c5e94700 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Unilibre |
| repository.mail.fl_str_mv |
repositorio@unilibrebog.edu.co |
| _version_ |
1814090572742262784 |
| spelling |
Cano Peñaloza, Raquel AmiraMoreno Pallares, EimanVarela Prieto, LourdesBornacelly Mendoza, Adriana PaolaCastillo Nevado, Oswaldo JesúsBarranquilla2023-12-13T21:01:13Z2023-12-13T21:01:13Z2023https://hdl.handle.net/10901/27874El objetivo es caracterizar el espectro de la enfermedad por hígado graso no alcohólico de causa metabólica (EHGNA) y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes adultos con diagnóstico de Diabetes Mellitus tipo 2 atendidos de forma ambulatoria en Barranquilla-Colombia de julio a diciembre de 2021. Se realizó una estudio observacional descriptivo documental con revisión de historias clínicas de corte retrospectiva con un componente analítico entre EHGNA en pacientes diabéticos y desenlaces cardiovasculares mayores no fatales. Se incluyeron 309 personas con diabetes atendidos en dos instituciones de referencia en Barranquilla: la Clínica General del Norte (CGN, n=162) y MiRed IPS (n=147), la prevalencia global de EHGNA fue del 67%, la esteatosis correspondió a un 50,81% (n=157), la esteatosis con algún grado de fibrosis ya sea significativa o avanzada se encontró en el 3,88% (n=12) y la cirrosis en el 12% (n=38), aportando una prevalencia global de fibrosis del 16,18% (n=50). La ecografía fue el estudio imagenológico más empleado para la detección y diagnóstico de esteatosis, la elastografía transitoria se realizó solo en 54 pacientes (17,48%). La prevalencia de obesidad en pacientes con diabetes y EHGNA fue del 36,82%, siendo la obesidad grado 1 la categoría más frecuente, la hipertensión arterial se presentó en el 76,33% de los casos, la dislipidemia en el 73,43%. Se encontró una mayor proporción de desenlaces cardiovasculares mayores no fatales como síndrome coronario agudo y fibrilación auricular en los pacientes con EHGNA (OR: 1,94; 95% IC:1,05-3,66; p=0.04). la conclusión es que la prevalencia de EHGNA en pacientes diabéticos atendidos en Barranquilla es del 67%, la prevalencia de fibrosis fue del 16,18%; además se observó una tendencia con efecto de riesgo con una mayor proporción de desenlaces cardiovasculares mayores no fatales como síndrome coronario agudo y fibrilación auricular en los pacientes con EHGNA (OR: 1,94; 95% IC:1,05-3,66; p=0.04) por lo que se requieren estudios analíticos adicionales que profundicen en el efecto de riesgo de EHGNA en la morbilidad cardiovascular.Universidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud -- Especialización en Medicina InternaThe Objective is To characterize the spectrum of metabolic nonalcoholic fatty liver disease (NAFLD) and its association with cardiovascular morbidity in adult patients diagnosed with type 2 Diabetes Mellitus treated on an outpatient basis in Barranquilla-Colombia from July to December 2021. A descriptive observational documentary study was conducted with a retrospective medical record review with an analytical component between NAFLD in diabetic patients and non-fatal primary cardiovascular outcomes. The study included 309 people with diabetes treated in two referral institutions in Barranquilla, the Clínica General del Norte (CGN, n=162) and MiRed IPS (n=147): Clínica General del Norte (CGN, n=162) and MiRed IPS (n=147), the overall prevalence of NAFLD was 67%, steatosis corresponded to 50.81% (n=157), steatosis with some degree of fibrosis either significant or advanced was found in 3.88% (n=12) and cirrhosis in 12% (n=38), contributing an overall prevalence of fibrosis of 16.18% (n=50). Ultrasonography was the most commonly used imaging study for detecting and diagnosing steatosis; transient elastography was performed only in 54 patients (17.48%). The prevalence of obesity in patients with diabetes and NAFLD was 36.82%, with grade 1 obesity being the most frequent category, arterial hypertension was present in 76.33% of cases, and dyslipidemia in 73.43%. A higher proportion of non-fatal primary cardiovascular outcomes, such as acute coronary syndrome and atrial fibrillation, was found in patients with NAFLD (OR: 1.94; 95% CI: 1.05-3.66; p=0.04). the Conclusions is the prevalence of NAFLD in diabetic patients attended in Barranquilla is 67%, the prevalence of fibrosis was 16.18%; furthermore, a trend with risk effect was observed with a higher proportion of non-fatal primary cardiovascular outcomes such as acute coronary syndrome and atrial fibrillation in patients with NAFLD (OR: 1.94; 95% CI:1.05-3.66; p=0.04) so further analytical studies are required to delve into the risk effect of NAFLD on cardiovascular morbidity.PDFDiabetes mellitusEnfermedad por hígado graso no alcohólico - EHGNAFactor de riesgo cardiovascularSíndrome coronario agudoFibrilación auricularDiabetes mellitusNon-alcoholic Fatty Liver Disease - NAFLDHeart disease risk factorsAcute coronary syndromeAtrial fibrillationHígado grasoDiabetes mellitusEnfermedades cardiovascularesCaracterización de hígado graso metabólico y su asociación con desenlaces cardiovasculares mayores no fatales en pacientes diabéticos tipo 2 atendidos de forma ambulatoria en Barranquilla durante julio a diciembre de 2021Tesis de Especializacióninfo:eu-repo/semantics/bachelorThesishttp://purl.org/coar/resource_type/c_7a1fEslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Vol. 10, Nature Reviews Gastroenterology and Hepatology. 2013. p. 330–44Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Alimentary Pharmacology and Therapeutics 2018; 48(7):696-703Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports 2021; 21 (5):15Kaya E, Yilmaz Y. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. Journal of Clinical and Translational Hepatology 2022; 10 (2); 329-338Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology 2021; 18 (4): 223-238Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019; 70 (3): 531-544Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver 54 Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice. 2022;28(5):528–62Rinella ME, Neuschwander-Tetri BA, Shadab Siddiqui M, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77:1797–835Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020; 69 (9): 1691-1705Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357Chen X, Ma T, Yip R, Perumalswami P V., Branch AD, Lewis S, et al. Elevated prevalence of moderate-tosevere hepatic steatosis in World Trade Center General Responder Cohort in a program of CT lung screening. Clin Imaging. 2020;60(2):237–43Chen X, Li K, Yip R, Perumalswami P, Branch AD, Lewis S, et al. Hepatic steatosis in participants in a program of low-dose CT screening for lung cancer. Eur J Radiol. 2017; 94:174–9Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ, et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. American Journal of Roentgenology. 2010;194(3):623–8Ochoa C. E, Calambás F. Hígado graso no alcohólico en consulta de gastroenterología. Repertorio de Medicina y Cirugía. 2017;26(4):225–30Prieto Ortiz JE, Pardo SS, Díaz LR, Pacheco SH. Hígado graso: Aspectos clínicos en un centro de tercer nivel en Bogotá - Período 2009-2013. Rev Colomb Gastroenterol. 2014;29(2):117–24Vanegas R. CM, Restrepo R. C, Vargas G. N, Marín C. AE, Martínez S. LM, Yepes D. CE, et al. Characterization of patients with non-alcoholic fatty liver disease in a highly complex colombian hospital in 2013. Rev Colomb Gastroenterol. 2014;29(4):342–6Escorcia E;, Marrugo W. Caracterización epidemiológica y clínica de la cirrosis hepatica en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017. Biociencias. 2018;13(1):17–30Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes and Metabolism 2021; 47 (2): 101215Bejarano Ramírez DF, Carrasquilla Gutiérrez G, Porras Ramírez A, Vera Torres A. Prevalence of liver disease in Colombia between 2009 and 2016. JGH Open 2020; 4: 603-610Prieto O JE, Sánchez P S, Prieto RG, Rojas D EL, González L, Mendivelso F. Características clínicas y descompensación en pacientes con cirrosis hepática atendidos en dos centros de hepatología en la ciudad de Bogotá D.C., 2010-2014. Revista Colombiana De Gastroenterología 2016; 31(1): 1–8Giraldo-Montoya Ángela M., Barraza-Amador M, Villa-Velásquez H, Martínez JW, Garcia-Castro G. Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012. Rev Méd Risaralda 2014; 20 (2):8686-94Lambis L, Belisario Solana J, Gastelbondo B, Romero D, Garrido D, Puello W, et al. Factores de riesgo asociados a hígado graso de origen no alcohólico en una población del Caribe Colombiano. Rev Col Gastroenterol 2016; 31 (2): 89-95Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. The Lancet 2021; 397: 2212–24. Elsevier B.VPerez M, Gonzáles L, Olarte R, Rodríguez NI, Tabares M, Salazar JP, et al. Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Prev Med (Baltim). 2011;52(2):174– 7López-Velázquez JA, Silva-Vidal K V., Ponciano-Rodríguez G, Chávez-Tapia NC, Arrese M, Uribe M, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Annals of Hepatology 2014;13(2):166-78Rojas YAO, Cuellar CLV, Barrón KMA, Arab JP, Miranda AL. Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysis. Annals of Hepatology 2022; 27(6):100706Budd J, Cusi K. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? American Journal of Medicine 2020;133(5):536-543Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, et al. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus. 2021;13(8): e17321Dokmak A, Lizaola-Mayo B, Trivedi HD. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. American Journal of Medicine 2021; 134 (1): 23-29. Elsevier IncYounossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology and Hepatology 2018; 15(1):11-20. Nature Publishing GroupZheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology 2018; 14 (2): 88-98Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, et al. NAFLD/NASH in patients with type 2 diabetes and related treatment options. Journal of Endocrinological Investigation 2018; 41(5): 509-521Glovaci D, Fan W, Wong ND. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Current Cardiology Reports 2019; 21 (4): 21Vargas-Uricoechea H, Casas-Figueroa LÁ. An Epidemiologic Analysis of Diabetes in Colombia. Annals of Global Health 2015;81(6):742-53Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Erratum: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018; 392(10160):1736- 1788Younossi ZM, Felix S, Jeffers T, Younossi E, Lam B, Nader F, et al. Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. Clinical Gastroenterology and Hepatology 2022; 20(5): e1149-e1156Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology 2022;42(6): e168-e185Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatology Communications 2018; 2(4):376-392Motamed N, Rabiee B, Poustchi H, Dehestani B, Hemasi GR, Khonsari MR, et al. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol. 2017;41(1):31–8Lee SB, Park GM, Lee JY, Lee BU, Park JH, Kim BG, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. J Hepatol. 2018;68(5):1018–24Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254(2):393–400Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS, et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World Journal of Gastroenterology 2013; 19(38): 6453–6457Perera N, Indrakumar J, Abeysinghe WV, Fernando V, Samaraweera WMCK, Lawrence JS. Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: An observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16(1):37Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2017; 11 Suppl 1: S209-S216Keskin M, Hayıroğlu Mİ, Uzun AO, Güvenç TS, Şahin S, Kozan Ö. Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST–Segment Elevation Myocardial Infarction. American Journal of Cardiology. 2017;120(10):1720–6Tsang SWC, Ng WF, Wu BPY, Chow DA, Li ETH, Wong TC. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia). 2006;21(1 PART1):116–21Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clinical Research in Cardiology 2021; 110(7):921-937Vasunta RL, Kesäniemi YA, Ylitalo AS, Ukkola OH. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. J Hypertens. 2012;30(10):2015–9Alkagiet S, Papagiannis A, Tziomalos K. Associations between nonalcoholic fatty liver disease and ischemic stroke. World Journal of Hepatology 2018; 10(7): 474–47Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology 2018;15(7):425- 439Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One. 2015;10(8): e0135329Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Valbusa F, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism. 2015;64(8):879–87Bonapace S, Valbusa F, Bertolini L, Pichiri I, Mantovani A, Rossi A, et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One. 2014 Feb 5;9(2): e88371Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study). PLoS One. 2015;10(11): e0142937Mantovani A, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. Liver International. 2019;39(4):758-769Long MT, Yin X, Larson MG, Ellinor PT, Lubitz SA, McManus DD, et al. Relations of liver fat with prevalent and incident atrial fibrillation in the framingham heart study. J Am Heart Assoc. 2017;6(5): e005227Lee SR, Han K Do, Choi EK, Oh S, Lip GYH. Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. Sci Rep. 2021;11(1):3737Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl): S17–31Saavedra-Chacón MF, Pérez S, Guevara LG, Saavedra-Chacón MF, Pérez S, Guevara LG. Enfermedad del hígado graso asociada con la disfunción metabólica. Una nueva propuesta para una dolencia en auge. Iatreia. 2021;34(3):241–52Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Curr Pharm Des. 2019;24(38):4574–86Graffigna M, Catoira N, Soutelo J, Azpelicueta A, Berg G, Perel C, et al. Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes. Rev Argent Endocrinol Metab. 2017;54(1):37–46Wells MM, Li Z, Addeman B, Mckenzie CA, Mujoomdar A, Beaton M, et al. Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. Can J Gastroenterol Hepatol. 2016; 2016:4930987Castera L, Yuen Chan HL, Arrese M, Afdhal N, Bedossa P, Friedrich-Rust M, et al. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64Boyum JH, Atwell TD, Schmit GD, Poterucha JJ, Schleck CD, Harmsen WS, et al. Incidence and Risk Factors for Adverse Events Related to Image-Guided Liver Biopsy. Mayo Clin Proc. 2016;91(3):329–35Stoopen-Rometti M, Encinas-Escobar ER, Ramirez-Carmona CR, Wolpert-Barraza E, Kimura-Hayama E, Sosa-Lozano LA, et al. Diagnóstico y cuantificación de fibrosis, esteatosis y hepatosiderosis por medio de resonancia magnética multiparamétrica. Revista de Gastroenterologia de Mexico 2017; 82(1):32-45Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Vol. 20, World Journal of Gastroenterology. 2014. p. 475–85Castellana M, Donghia R, Guerra V, Procino F, Lampignano L, Castellana F, et al. Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. A meta-analysis. J Clin Med. 2021;10(9):1877Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics. 2022;12(2):407Rada G, Roa M. Qué son y cómo se interpretan los outcomes compuestos. Rev Med Chil. 2009;137(11):1523–6Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal 2020; 41:111-188Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl 1):S158– S190Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl 1): S49–S67Schattenberg JM, Allen AM, Jarvis H, Zelber-Sagi S, Cusi K, Dillon JF, et al. A multistakeholder approach to innovations in NAFLD care. Communications Medicine. 2023;3(1Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43(1):83- 95Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471–8Kwok R, Choi KC, Wong GLH, Zhang Y, Chan HLY, Luk AOY, et al. Screening diabetic patients for nonAlcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut. 2016;65(8):1359–68Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. 2021;121:154752Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2018;16(2):198-210.e2Han S, Choi M, Lee B, Lee HW, Kang SH, Cho Y, et al. Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gut Liver. 2022;16(6):952–63Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of noninvasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis. Gut 2022; 71:1006–1019Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A metaanalysis study. Hepatology Research 2016; 46(9):862-70Pérez-Gutiérrez OZ, Hernández-Rocha C, Candia-Balboa RA, Arrese MA, Benítez C, Brizuela-Alcántara DC, et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Ann Hepatol. 2013;12(3):416–24Aschner P, Gagliardino JJ, Ilkova H, Lavalle F, Ramachandran A, Mbanya JC, et al. Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia. 2020;63(4):711–21Huayanay-Espinoza IE, Guerra-Castañon F, Lazo-Porras M, Castaneda-Guarderas A, Thomas NJ, GarciaGuarniz AL, et al. Metabolic control in patients with type 2 diabetes mellitus in a public hospital in Peru: A cross-sectional study in a lowmiddle income country. PeerJ. 2016;2016(10): e2577Osuna Pérez M, Rivera MC, Bocanegra C de J, Lancheros A, Tovar H, Hernández JI, et al. Caracterización de la diabetes mellitus tipo 2 y el control metabólico en el paciente hospitalizado. Acta Médica Colombiana. 2014;39(4):344–51Meyersohn NM, Mayrhofer T, Corey KE, Bittner DO, Staziaki P V., Szilveszter B, et al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clinical Gastroenterology and Hepatology. 2021;19(7):1480-1488.e14Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867–75Ismaiel A, Popa SL, Dumitrascu DL. Acute coronary syndromes and nonalcoholic fatty liver disease: “Un affaire de coeur.” Canadian Journal of Gastroenterology and Hepatology 2020; 30:8825615van Kleef LA, Lu Z, Arfan Ikram M, de Groot NMS, Kavousi M, de Knegt RJ. Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study. J Hepatol. 2022;77(4):931–8http://purl.org/coar/access_right/c_abf2THUMBNAILBornacelly.pdf.jpgBornacelly.pdf.jpgPortadaimage/jpeg109235http://repository.unilibre.edu.co/bitstream/10901/27874/5/Bornacelly.pdf.jpg96871d7132094f77451a2dc4998a3b8eMD55BORNACELLY.pdf.jpgBORNACELLY.pdf.jpgIM Thumbnailimage/jpeg13478http://repository.unilibre.edu.co/bitstream/10901/27874/6/BORNACELLY.pdf.jpg0e23061c2ed41f730db0ea3e882a467eMD56FORMULARIO AUTORIZACION.pdf.jpgFORMULARIO AUTORIZACION.pdf.jpgIM Thumbnailimage/jpeg28779http://repository.unilibre.edu.co/bitstream/10901/27874/7/FORMULARIO%20AUTORIZACION.pdf.jpg866424b5b768a79ad3f5670dcfda3d6cMD57LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/27874/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALBORNACELLY.pdfBORNACELLY.pdfArchivo de Tesis MEDINT 2023application/pdf2078657http://repository.unilibre.edu.co/bitstream/10901/27874/1/BORNACELLY.pdfca42e0bf20d3691ab4c004c24ad6ae9bMD51FORMULARIO AUTORIZACION.pdfFORMULARIO AUTORIZACION.pdfapplication/pdf1475034http://repository.unilibre.edu.co/bitstream/10901/27874/2/FORMULARIO%20AUTORIZACION.pdf500a42f7f8c0d6a15b257b46c5e94700MD5210901/27874oai:repository.unilibre.edu.co:10901/278742024-08-28 06:01:15.252Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.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 |